Introduction
Intercellular signaling by ®broblast growth factor (FGF) via the ®broblast growth factor receptor (FGFR) controls many aspects of cell fate in animal growth and development (McKeehan et al., 1998; Ornitz, 2000) . FGF1 and FGF2, the two prototypic FGF proteins, lack a signal peptide at their 5' ends and are found in the cytosol; however, both factors seem to be released from cells through a nonclassical secretory pathway (Mignatti et al., 1992; Tarantini et al., 1998) . Intriguingly, both FGF1 and FGF2 have also been found in the nucleus. The precise function of these nuclear forms of FGF1 and FGF2 remains unclear but their physical presence in the nucleus appears to be essential for their mitogenicity (Mehta et al., 1998) . FGF1 is unique among FGFs in that it binds with high anity to all known receptor isoforms (Ornitz et al., 1996) . Although the principal signal transduction pathway used by FGFRs is the Ras/MAP kinase pathway, the complexity of FGF signaling is compounded by the fact that there are at least 22 FGF ligands and four FGF receptors. Because many cells have FGFRs, the question arises as to how the speci®city of a cell's response to a particular FGFR ligand is controlled. Part of the answer lies in the state of the cell when the FGFR/Ras/MAP kinase cascade is initiated. It follows, therefore, that during normal development speci®c FGFR ligands must be present at discrete time points in order to maintain the precise spatial and temporal regulation of the FGFR signaling pathway in any given cell type.
In the normal mouse, FGF1 expression is most prevalent in cranial nerve nuclei throughout the pons and medulla, and in the substantia nigra, cholinergenic neurons of the basal forebrain, and several other subcortical neuronal populations (Eckenstein et al., 1994; Alam et al., 1996) . We have shown previously that multiple promoters tightly control the expression of the FGF1 protein (Myers et al., 1993) . Thus, promoter 1A is active in the kidney (Myers et al., 1995a) , 1B in brain (Myers et al., 1995b) , 1C and 1D in a variety of cultured cells including vascular smooth muscle cells (Chotani and Chiu, 1997) . The 1A and 1B promoters are constitutively active in their respective cell types. In contrast, dierent biological response modi®ers can induce the 1C and 1D promoters, including serum and transforming growth factor b (Chotani and Chiu, 1997) . The 540-bp sequence upstream of the 1B transcription initiation site is sucient to drive the expression of a heterologous luciferase reporter in cultured cells (Myers et al., 1995b) , and an 18-bp sequence within this region is important for the regulation of brain-speci®c gene expression (Ray et al., 1997) . Furthermore, regulation occurs through the binding of the 18-bp sequence to a brain-speci®c 37-kDa protein (Myers et al., 1995b) and a ubiquitous basic helix ± loop ± helix protein, E2-2 (Liu et al., 1998) . In this study, we examined the possibility that the same 540-bp sequence of FGF-1B promoter can regulate the expression of a reporter gene, such as the SV40 large T antigen, in transgenic mice.
A staged, linear model of cancer progression has been proposed, in which multiple individual mutations in oncogenes and tumor suppressor genes are required for the onset of malignancy. It appears that multiple events are necessary for the development of sporadic solid tumors (Fearon and Vogelstein, 1990; Bergers et al., 1999) . SV40 large T antigen, acts as a strong transforming protein through its binding to, and consequent inactivation of, two major cellular tumor suppressors, pRb and p53. Inactivation of both tumor suppressor activities appears to be important for tumorigenesis. Transgenic mice that contain a mutant SV40 T antigen that perturbs pRB function but does not aect p53 function, develop tumors more slowly than those containing the wild-type T antigen. These results suggest that p53-dependent apoptosis, occurring in response to oncogenic events, is a critical regulator of tumorigenesis (Symonds et al., 1994) .
To study tumorigenesis in the central nervous system, we have generated transgenic mice containing the SV40 large T antigen under the control of the brain-speci®c FGF1 promoter. The resulting transgenic mice are predisposed to inheritable brain tumors. In mature animals, tumors lacked terminal dierentiation markers for astrocytes (glial ®brillary acidic protein) or neurons (synaptophysin and neuron-speci®c enolase). However, they expressed high levels of proliferating cell nuclear antigen and vimentin, markers for proliferating cells. These markers are consistent with the tumor being at an early stage of dierentiation, thus raising the possibility that primitive neuroectodermal cells in the developing murine brain are susceptible to malignant transformation by a single exogenous stimulus.
Results
We have shown previously that the FGF1B promoter from 7540 to +31 dictated the expression of a downstream luciferase reporter gene, designated F1B-Luc, in a cell-speci®c manner (Myers et al., 1995b; Ray et al., 1997) . Thus, F1B-Luc is expressed in FGF1B-positive U-1240 MG cells, but is not expressed in FGF1B-negative U-1242 MG cells. Additional upstream DNA sequences up to 73900 did not contribute additional luciferase activities (data not shown). Therefore, FGF1B promoter (nucleotides 7540 to +31) was ligated upstream of the SV40 immediate early gene sequence. The resultant F1B-Tag plasmid DNA (Figure 1 ) was linearized at the unique BamHI site and microinjected into zygotes. Embryos were implanted into surrogate mother mice at The Ohio State University Transgenic Facilities. The transgenic mice were identi®ed by PCR analysis using genomic DNA isolated from their tails as templates (data not shown). Those that were positive with a 312-bp amplicon were subjected to Southern blotting analysis to verify the presence of the F1B-Tag transgene.
Three founder mice (88, 94, and 98) were initially identi®ed and mated. Representative Southern blots of the F2 generation of each of the three families are shown in Figure 2 . The ®lter was hybridized to a 1.2-kbp HindIII fragment derived from the SV40 immediate early gene region. Figure 2a shows the ospring of F1 transgenic mice 98-29, 98-25 and 88-11 . Each family had a unique pattern of hybridizing bands, indicating a distinct transgenic DNA integration site. In contrast, two dierent hybridization patterns for ospring of mouse 94-8 were detected (Figure 2b ): mice 94-8-84 and 94-8-86 showed higher intensity signals than mice 94-8-87, 94-8-90 and 94-8-91 , indicating that the former contains a higher copy number of the transgene. Mice with the higher copy number also had an additional band at 10 kbp ( Figure  2b ), which helped to identify mouse 94-8-82 as a highcopy number animal. The apparent low intensity of hybridizing bands in this lane was due to the loading of less DNA, which was visualized by staining the gel with ethidium bromide. The results suggest that Figure 1 Restriction map of F1B-Tag construct. Nucleotides 7540 to +31 of human FGF-1B promoter and nucleotides 5171 ± 2533 of SV40 immediate early genes were cloned into the SmaI-BamHI sites of pGL2-Basic. The enhancer sequence commonly known as the 239-bp NcoI-PvuII fragment, extending from nucleotides 37 ± 275 of the SV40 genome, is not included in our construct. The thick line represents the human FGF-1B promoter sequence. The hatched box represents the SV40 immediate early genes. Dashed lines indicate the introns for the large T and small t antigens. ATG and TAA are the translational initiation and termination codons for SV40 T antigen. The polyadenylation site is symbolized by An. Dotted lines represent the vector sequence derived from pGL2-Basic plasmid. As such, an additional copy of the SV40 polyadenylation signal sequence is located upstream from the FGF1 promoter to prevent stray transcription initiated from¯anking host genomic sequences Figure 2 Southern blots of F1B-TAg transgenic mouse DNA. Mouse-tail DNA was digested with BamHI, separated on an agarose gel, and blotted to a ®lter. The ®lter was hybridized to a 1.2-kbp HindIII fragment derived from SV40 immediate early gene sequences. Each of the four lines has a distinct pattern of hybridization, indicating dierent integration sites of the transgenic DNA. (a) shows the ospring of mice 98-29, 98-25 and 88-11. (b) shows the ospring of mouse 94-8. Lambda DNA digested with HindIII was used as a molecular weight marker and the sizes in kbp are indicated on the left of each panel founder 94 had two non-allelic integration sites (denoted H and L for high-and low-copy number, respectively).
A partial pedigree of each of the three families, showing that the transgene was inherited according to Mendel's law, is depicted in Figure 3 . The transgenic ospring of 94-8 showed the inheritance of either the H or L locus, suggesting that 94-8 inherited both the H and L loci from her founder father. All six transgenic ospring of 94-16, as well as those up to generation F5, inherited only the L locus (data not shown). Similarly, all ®ve transgenic ospring of 94-8-82, as well as those up to the F5 generation, inherited only the H locus (data not shown). Thus, we concluded that the two integration sites in founder 94 have been segregated, and the two lines are referred to as 94H and 94L, respectively (Figure 3) .
The life span of transgenic animals was considerably shorter than that of normal mice of the parent strain. The mean (+standard deviation) survival time across four generations, excluding mice sacri®ced for early data points, was 183(+38), 178(+22), 166(+25) and 212(+35) days for 88, 98, 94H and 94L mice, respectively. Older animals appeared hunched and lethargic, and some animals were ataxic.
Although tumors were occasionally observed in other organs, such as the pancreas (Table 1) , each of the four transgenic lines manifested brain tumors with complete penetrance. Within the central nervous system, the apparent sites of tumor origin were restricted to the brain stem, generally sparing the cerebral cortex, hippocampus, cerebellum and spinal cord. Tumors were comprised of small cells with scanty cytoplasm and regular round to ovoid nuclei that were stained at moderate intensity by cresyl fast violet ( Figure 4a ) and hematoxylin (Figure 4b ), clearly delineating the tumors from surrounding tissue. Tumors of dierent sizes were distributed along myelinated ®ber tracts, suggesting that in®ltrating tumor cells followed these structures. In strain 88 and 98 mice, foci were entirely restricted to the caudal pontine regions of the brain stem, and appeared to originate in the dorsal tegmental region, at the rostral surface of the fourth ventricle. In general, tumor foci in the 98 strain were distributed over a larger area than those of line 88 animals. As with the 88 and 98 lines, major foci were also concentrated in the tegmental region in adult mice of the 94H and 94L lines (Figure 4c, d) . Additional smaller foci were scattered in a diagonal stream from the pontine central gray into the interpeduncular nucleus at the ventral surface of the brain stem. However, unlike 88 and 98 mice, tumor cells were also present in all subnuclear regions of the thalamus, and in the striatum (caudate, putamen, accumbens), ventral forebrain (olfactory tubercle, amygdala) (Figure 4a, b) , and olfactory bulbs (data not shown). Foci were distributed dierentially in 94L and 94H mice: In 94L animals, tumors in the pontine gray-interpeduncular stream were far smaller and less frequent than in 94H animals, while tumors in the thalamus, striatum, forebrain and olfactory bulbs were more numerous and far larger. Although the degree to which the tumors invaded the brain stem varied across the four lines, within each line the place of origin and ®nal distribution of major foci were highly reproducible across animals. The distribution of CNS tumors in each transgenic line is schematized in Figure 5 , and their frequency is shown in Table 2 .
Abnormalities were also observed in speci®c brain regions apparently unaected by tumor activity. Although the cerebellum was generally spared, it was frequently¯attened and lobules 1 through 6 were somewhat agranular ( Figure 4a ). This was likely the result of increased cerebellar compression between the enlarging tumor and the cranium, possibly accounting for the ataxia observed in some of the older mice. In one anomalous 94H F3 generation mouse (94-8-82-28), tumor cells, apparently associated with the ependymal lining of the fourth ventricle, extended from the dorsal surface of the medulla into posterior cerebellar folia 1 and 2 (Figure 4e ). These cells in®ltrated tangentially through the molecular and Purkinje cell layers into the granule cell layer. In addition, in some animals patches of ependymal lining at the rostral ventricular surface appeared thickened and distorted, extending into the underlying brain tissue accompanied by enlarged blood vessels (Figure 4f ). Clustered tumor cells within the Virchow-Robin spaces and in the subependymal region suggested that these are highly motile cells that migrate in association with these structures, mimicking the secondary structures of Scherrer. In older mice (P160 onward), the ventricles were greatly distended and several mice exhibited obstructive hydrocephalus. In several 94H mice, irregularly shaped tangles of ependymal lining were present within the fourth ventricle (data not shown).
Immunocytochemical markers known to be present in neurons, glia, vascular endothelial cells, tumor cells, and proliferating cells (Table 3) were used to identify the location and cell type from which the tumors originated, and the magnitude of the proliferating population. An antibody to the SV40 T antigen identi®ed the smallest cellular aggregates, which at early time points (P26-30) were undetectable using standard histological procedures. In each of the four transgenic lines, scattered . This animal is unusual in that cerebellar lobules 1 and 2 are invaded by proliferating cells (small arrows) organized in perpendicular arrays from the pial membrane through the molecular layer. These ectopic cells may be following major blood vessels, which are organized similarly. The main tumor (tm) lies ventral to cerebellar lobule 1. (f) The ependymal membrane (ep) adjacent to the dorsal tegmental nucleus, is thickened by proliferating cells, and is heavily vascularized (arrows). BS, brain stem; cb, cerebellum; ct, cortex; ep, ependymal membrane; g, granule cell layer; h, hippocampus; ic, inferior colliculus; ip, interpeduncular nucleus; m, molecular layer; P, Purkinje cell layer; st, striatum; tg, tegmental area; th, thalamus; tm, tumor; IVV, fourth ventricle; LV, lateral ventricle; 1,6, cerebellar folia 1 through 6. Scale bars: (a,e), 500 mm; (b,c), 250 mm; (d,f), 100 mm small T antigen-positive cells became detectable in the pontine raphe and dorsal tegmental nuclei by postnatal day (P)26 (Figure 6a,b) . By P30, additional small aggregates were present throughout the pontine central gray (sphenoid, and dorsal and ventral tegmental nuclei), radiating rostroventrally and mediolaterally into the pons and medulla. These smaller foci followed the general pathways of the decussation of the superior cerebellar peduncle, the mammillotegmental tract, and associated blood vessels. Tumor foci in P26-P35 mice contained moderate levels of GFAP, and lower levels of vimentin (Figure 6c,d) . As the animals matured, many of the smaller foci became fused into multicellular masses of variable size, spreading from the pontine central gray into the interpeduncular nucleus at the ventral pontine surface (Figure 7a ). Punctate PCNA staining (Figure 7b) , indicating proliferating cells in the G1 and S phases of the cell cycle, became increasingly intense. In mature mice, high levels of vimentin were present (Figure 7c ), but GFAP staining was generally absent within the perimeter of all major foci (Figure 7d) , thus reversing the staining pattern observed in the younger animals (Table 3 ). All tumor foci were negative for FGF1 (Figure 7e ), but continued to exhibit high levels of T antigen (Figure 7f) .
Neuronal cell markers, including neuron-speci®c enolase (NSE) and synaptophysin, and glial marker S-100, although present within their appropriate cell types in areas unaected by tumor, were either completely undetectable or present only in scattered cells within the tumor boundary, probably in entrapped, non-neoplastic cells (Figure 8a ± c) . Enlarged blood vessels, identi®ed by endothelial cell markers CD 31 and von Willebrand factor (Takahashi et al., 1994) , invaded all larger tumor foci (Figure 9a ± c) . For a tumor to expand beyond a prevascular size, it must produce angiogenesis stimulators (Hanahan and Folkman, 1996) . Vascular endothelial growth factor (VEGF), a potent angiogenic factor (Risau, 1997) , is expressed in blood vessels within F1B-Tag tumors (Figure 9d ).
Discussion
We have generated four lines of transgenic mice using the brain-speci®c FGF-1B promoter to drive the expression of SV40 large T antigen, which manifests its transforming potential through inactivation of two major cellular tumor suppressor proteins, p53 and pRb (Symonds et al., 1994) . Because the mouse FGF-1B promoter is structurally similar to the human FGF-1B promoter (Alam et al., 1996; Madiai et al., 1999) , we reasoned that the human FGF-1B promoter should function in mouse cells. Each of the transgenic mice developed brain stem tumors of various sizes, most consistently in the caudal pons. Within this region, the location of F1B-Tag tumors was highly reproducible, in that all four lines developed tumors at the anterior surface of the fourth ventricle near the midline, a region known for its susceptibility to tumor formation.
Southern blotting analysis showed that the copy numbers of the four transgenic lines ranked as follows: 94H498488494L (Figure 2 ). The dosage of the transgene is re¯ected in the size of the pontine tumors formed in each line. Thus, 94H and 98 exhibited larger tegmental tumors than 88 mice, which, in turn, had more extensive tumors than 94L animals ( Figure 5 ). Furthermore, the higher copy number also re¯ected shorter survival time. These results suggest that the amount of T antigen in each of the transgenic lines is directly proportional to the severity of the brain tumor. It is noted that the tumor was more widely spread in the 94H and 94L lines than in the 88 and 98 lines, often extending anteriorly into the thalamus, striatum and olfactory bulbs ( Figure 5) . Therefore, the integration sites of the transgene may also contribute to the spatial distribution of the brain tumor.
Tissue-specific expression of the transgene
In previous studies, we have shown that at least four dierent FGF1 transcripts are expressed in dierent tissues through alternative promoter usage and alternative splicing (Myers et al., 1993; Chotani and Chil, 1997) . Although alternative splicing is used frequently for cell-speci®c expression in the vertebrate nervous system, little is known about the mechanism involved (Black et al., 1998) . The 540-bp of FGF-1B promoter used in the transgene construct (Figure 1 ) is sucient to drive a heterologous luciferase reporter gene in U-1240 MG glioblastoma cells that express FGF-1B transcript in a transient transfection assay (Myers et al., 1995b; Ray et al., 1997; Liu et al., 1998) . Furthermore, we showed that the F1B-Tag transgene, when stably transfected into U-1240 MG cells, can support the expression of T antigen (Cho et al., 2000; Chiu et al., unpublished results) . In light of the above studies, it is surprising that the tumors, although expressing T antigen, did not express FGF1 (Figure 7e ), as in wildtype mouse brain, smaller FGF1-positive cells are scattered throughout the subependymal region, rostral to the fourth ventricle (data not shown). A possible explanation is that although the brain-speci®c FGF-1B promoter contains sucient information to drive the expression of the T-antigen transgene in tumor cells, as the antigen is expressed the cells become arrested as a more pluripotent precursor cell type, which prohibits the continued expression of endogenous FGF1 gene. Such an interpretation would imply that additional sequences upstream of the 540-bp sequence used in this study may be required for a more faithful recapitulation of endogenous FGF1 gene expression. An alternative, and less likely, explanation would be that the FGF1 promoter has nothing to do with the tissuespeci®c expression of the transgene. This is unlikely as the SV40 early gene sequence itself, without an inherent or heterologous promoter element, does not induce tumors of any kind (Hanahan, 1985; Messing et al., 1985) . Furthermore, other promoters also generate distinct SV40 tumors of neuroectodermal origin, but in dierent brain regions (Fung and Trojanowski, 1995) , and the insulin promoter induces tumors in pancreatic Langerhans cells (Hanahan, 1985) .
Histogenesis of the pontine tegmental nuclei
The nervous system evolves from a layer of strati®ed multipotent stem cells in the primitive neuroectoderm (Davis and Temple, 1994) . Normal cells undergo highly orchestrated developmental processes involving cell proliferation, migration, and dierentiation. In each of the four transgenic lines, F1B-Tag tumors originated within the dorsal pons, speci®cally in the dorsal tegmental and/or pontine raphe nuclei. The histogenesis of these closely associated regions has been described in detail (Taber-Pierce, 1966) . Although a small number of cells in the dorsal tegmental nuclei appear to originate the rhombic lip, the genesis of the great majority of tegmental precursors occurs on gestation days 12 ± 13 in the ependyma of the fourth ventricle. These primitive cells are located within a limited region of the basal plate, just lateral to the midline, at the level of the pontine¯exure. Similarly, neuroblasts giving rise to the pontine raphe, a narrow, midline structure dorsal to, and abutting, the dorsal tegmental nuclei, arise slightly earlier, on gestation days 10 and 11, from the same ventricular region (Taber-Pierce, 1966) . Within 24 ± 48 h of birth, neuroblasts destined for both regions migrate to their adult position on either side of the midline, ventral to the medial longitudinal fasciculus. Epigenetic in¯uences during any of these embryonic processes may be sucient to block normal cellular development and lead to the formation of primitive neuroectodermal tumors at a later stage (Yachnis et al., 1994) . showing a large tumor extending throughout the dorsal and ventral tegmental nuclei (tg) and pontine raphe nucleus, and into the fourth ventricle. A separate tumor is located in the interpeduncular nucleus (ip) at the ventral surface of the brain stem. High levels of punctate PCNA staining are detected throughout the tumor (b); the vimentin antibody is distributed similarly (c). In a mature animal, GFAP staining (d) is present at the periphery of the tumors and throughout tracts (small arrows) joining the two major foci; however, it is largely absent from the body of the tumor. All tumors were FGF1-negative (e) and T antigen-positive (f). cb, cerebellar cortex; ic, inferior colliculus; ip, interpeduncular nucleus; om, occulomotor nucleus; tg, tegmental nuclei;. Large arrows in (e) and (f) indicate the ventral border of the tumor. Scale bars: (a ± d), 500 mm; (e ± f), 250 mm
The commitment of CNS progenitor cells to neuronal or glial lineage, and the maturation of neurons and glia, are signaled by the coordinated expression of many developmentally regulated proteins (Anderson, 1999) . For example, vimentin is expressed in progenitor cells that retain the plasticity to dierentiate into cells of neuronal or glial lineage; it is replaced by synaptophysin and neuron-speci®c enolase in mature neurons, and by GFAP in astrocytes (Pekny et al., 1999) . Three dierent intermediate ®laments, nestin, vimentin, and GFAP, are found in astrocytes and their precursors. In immature astrocytes, nestin and vimentin are the main intermediate ®laments, whereas maturing and adult astrocytes contain vimentin and GFAP, respectively. During reactive gliosis, nestin production is resumed, and vimentin and GFAP expression is upregulated in activated astrocytes (Eng and Ghirnikar, 1994; Frisen et al., 1995) .
Comparison with other primitive neuroectodermal tumors in transgenic mice
Comparison with widely used tumor markers suggests that the F1B-Tag tumor may fall into the general category of the primitive neuroectodermal tumor (PNET). Currently, there are several transgenic animal models that recapitulate key features of human PNETs. They invariably contain the SV40 T antigen driven by various promoters, including those for tyrosine hydroxylase, phenylethanolamine N-methyltransferase, luteinizing hormone b-subunit, and interphotoreceptor retinoid-binding protein (Fung and Trojanowski, 1995) . Members of each of these transgenic lines develop PNETs arising in dierent, yet distinct, brain regions. Our F1B-Tag mice dier from these mice, not only in the site of tumor formation, but also in the stage of dierentiation. Speci®cally, tumors in each of the four transgenic lines mentioned above expressed synaptophysin (Fung et al., 1994) , whereas the F1B-Tag tumor does not express any of the neuronal markers tested, including synaptophysin and neuronspeci®c enolase (Figure 8) . Neither is the F1B-Tag tumor likely to be an oligodendroglioma or choroid plexus papilloma, as it expressed vimentin, which is absent from tumors of the latter types (Reifenberger et al., 1987) . Furthermore, the F1B-Tag tumor is unlikely to be an astrocytoma as the mature tumor does not express GFAP. It is possible, therefore, that during early development, FGF1-containing progenitor cells, under the in¯uence of the T antigen, do not progress along the neural lineage to the point of expressing either glial or neuronal markers. Such cells are prohibited from reaching terminal dierentiation, setting the stage for tumorigenesis, and providing a unique in vivo system in which to study the induction and progression of PNETs.
Neural stem cells and origin of tumor cells
Until recently, it was believed that adult brains were doomed to a constant, steady decline. It appeared that, shortly after birth, neurons lost their ability to grow and cells that died could not be replaced. However, in the past few years, it has been reported that certain kinds of neurons can grow in adult brains (Temple and AlvarezBuylla, 1999) . Self-renewing, totipotent embryonic stem cells may provide a virtually unlimited donor source for transplantation (Brustle et al., 1999) . Recently, two groups have identi®ed glial cells in the dentate gyrus of the hippocampus as a source of proliferating neurons. However, it is not clear whether the glial cells were derived from the ependymal layer (Johanson et al., 1999) or the subventricular zone (Doetsch et al., 1999) of the lateral ventricles. Although these precursor cells were conveniently de®ned as glial cells because they expressed GFAP, it is quite possible that these GFAPpositive cells were precursors of both glial and neuronal lineages (Barres, 1999) . The resolution of this controversy will require identi®cation of additional markers that identify speci®c precursor cells. Our tumor cells, which lack both GFAP and synaptophysin, may provide a useful source for generating these neural stem cell markers.
Materials and methods

Construction of plasmid DNA
Nucleotides 7540 to +31 of the human FGF-1B promoter (Myers et al., 1995b) and nucleotides 5171 ± 2533 of the SV40 immediate early gene (Tooze, 1981) were cloned into the SmaI-BamHI sites of pGL2-Basic (Promega). The resultant plasmid was designated pF1B-Tag. The enhancer sequence, commonly known as the 239-bp NcoI-PvuII fragment, which extends from nucleotides 37 ± 275 of the SV40 genome, is not included in our construct. Within the enhancer sequence are the two 72-bp repeats, one from nucleotides 107 ± 178, and the other from nucleotides 179 ± 250 of the SV40 genome. This enhancer sequence has been shown to dictate expression of transgenes, speci®cally in the choroid plexus, and results in tumorigenesis in this area . Others (Hanahan, 1985) have used a BglI-BamHI fragment, slightly longer than that used in the present study, which contains an additional 73 bp of 5' untranslated sequence, from BglI (nt. 5243) to HindIII (at nt. 5171) sites. This fragment does not cause tumor in transgenic mice (Hanahan, 1985; .
Production of transgenic mice
Microinjection of BamHI-linearized pF1B-Tag plasmid DNA was carried out by Dr Jan Parker-Thornburg, Director of Transgenic Facilities at The Ohio State University. The inbred mouse strain FVB/N was used in the transgenic experiments. Fertilized eggs were obtained from superovulated females induced by intraperitoneal injection of pregnant mare serum followed by human chorionic gonadotropin, after a 48-h interval. All DNA for microinjections was suspended in microinjection buer (10 mM Tris-HCl, pH 7.4/ 0.1 mM EDTA) to a concentration of 1 ± 10 ng/ml. Injected eggs were implanted the same day into the oviducts of pseudopregnant CD1 females and were allowed to develop to term. Transgenic mice were identi®ed by PCR and con®rmed by Southern blotting analysis of mouse-tail DNA.
Polymerase chain reaction and Southern blotting analysis FVB/N mouse tails were incubated at 558C overnight with lysis buer [100 mM TrisHCl (pH 8.3), 5 mM EDTA, 200 mM NaCl, 0.2% SDS, and 0.1 mg/ml Proteinase K], followed by extraction of genomic DNA with phenol/chloroform. PCR ampli®cation was carried out in a 50 ml volume containing 250 ng of mouse genomic DNA as the template, 0.4 mM each of sense and antisense primer, 200 mM dNTPs, 4 mM MgCl 2 , and 1.25 units Taq DNA polymerase. After the initial denaturation at 948C for 5 min, 25 cycles of 1 min denaturation at 948C, 1 min annealing at 558C, and 1 min extension at 728C were performed. The sense primer, L210 (5'-GAGAGTCTCCGAGCCACGACCTGCTGTTTC-CCTGGCAACTC-3'), was derived from nucleotides 7507 to 7467 of the FGF-1B promoter. The antisense primer, L213 (5'-GTTTATCAGTAGAGGGGACCTGCCTTTAGA-CAACCGCCCACT-3'), was derived from nucleotides 7196 to 7237 of the FGF-1B promoter (Myers et al., 1995b) . Ten microliters of the ampli®ed product was separated on a 3% agarose gel. For Southern blotting, 10 mg of genomic DNA was digested with BamHI or EcoRI and separated on a 1% agarose gel. A 1.2 kb HindIII fragment, isolated from pF1B-Tag and labeled with a-32 P-dATP using the Multiprimer DNA Labeling System (Amersham), was used as a probe. Hybridization was performed overnight at 628C with 1610 6 c.p.m./ml of the probe, as described (Chiu et al., 1990) .
Immunohistochemistry FVB/N mice were ®rst anesthetized by intraperitoneal (IP) injection using 150 mg/kg of a 50 mg/ml stock solution of sodium pentabarbitol. Mice were perfused using 50 ml phosphate buered saline, pH 7.3 (PBS), followed by 50 ± 75 ml of 4% paraformaldehyde in 0.1 M phosphate buer, pH 7.2. The brain was then dissected and immersion-®xed in 4% paraformaldehyde at 48C for 2 ± 24 h followed by overnight cryoprotection in 30% sucrose at 48C. Tissues were frozen in dry ice and cryostat-sectioned for immunohistochemical studies. Immunohistochemistry was carried out on 40-mm free-¯oating sagittal sections at room temperature. Endogenous peroxidase was blocked with 3% H 2 O 2 /10% methanol in PBS, and rinsed three times with PBS. Tissues were then blocked using 5% normal serum in PBS and incubated overnight in primary antibodies that were diluted in PBS containing 1% normal sera. The concentration of the primary antibodies were as follows: Anti-FGF1 1 : 800 (Santa Cruz Biotechnology, #sc-1884); anti-T antigen 1 : 100 (Santa Cruz Biotechnology, #sc-148), anti-GFAP 1 : 150 (Santa Cruz Biotechnology, #sc-1670), anti-NSE 1 : 100 (Biogenix, #AR055-5R), anti-vWF 1 : 10,000 (Dako Corp., #A0082), anti-VEGF 1 : 800 (Santa Cruz Biotechnology, #sc-1836),
anti-PECAM-1 (CD31) 1 : 1000 (Santa Cruz Biotechnology, #sc-1506), anti-synaptophysin 1 : 1000 (Dako Corp., #A0010), anti-S-100 1 : 400 (Novo Laboratories), and anti-vimentin 1 : 800 (Santa Cruz Biotechnology, #sc-7557). On the second day, tissues were rinsed three times with PBS for a total of 10 min, followed by incubation in the corresponding biotinylated secondary antibody, obtained in the Vectastain Elite ABC kit (Vector Labs), for 35 min. Tissue was rinsed three times with PBS for a total of 10 min, incubated in ABC reagent (ABC kit, Vector Labs) for 1 h, rinsed three times with PBS for a total of 10 min, and developed using 3,3'-diaminobenzidine (DAB) tetrahydrochloride (Sigma) and 0.01% H 2 O 2 in PBS. In addition, some sections were treated with DAB plus nickel chloride to provide a grayish-black staining result. For all specimens, corresponding sections were taken for Cresylecht Fast Violet (CV) staining. The primary antibody was omitted in control sections. No speci®c staining, other than occasional weak staining of endothelial cells, was seen with the secondary antibody alone.
Histopathological examination of mouse tissues
Transgenic mice were examined closely for gross behavioral abnormalities twice a week. Animals were sacri®ced at various ages between postnatal day (P) 26, and P289. Histopathological examinations were performed on normal and tumor tissues harvested from the transgenic mice. Tissues were ®xed in 10% neutral buered formalin and processed for paran embedding. Five micrometer tissue sections were prepared and stained with hematoxylin and eosin.
